Summary of Alkermes plc (NASDAQ:ALKS) Ratings

Big Money Sentiment increased to 1.17 in 2018 Q3. It has change of 0.35, from 2018Q2’s 0.82. The ratio improved due to Alkermes plc positioning: 22 sold and 61 reduced. 40 funds amassed holdings and 57 increased holdings. Investors holded 152.15 million in 2018Q2 but now own 152.54 million shares or 0.25% more.
Mark Sheptoff Financial Planning Ltd Llc reported 150 shs. Blackrock reported 9.97 million shs stake. Korea Corp has 226,581 shs for 0.04% of their capital. Ptnrs Lc holds 83,269 shs. Meeder Asset Mgmt has invested 0% in Alkermes plc (NASDAQ:ALKS). 1.03 million are owned by Meditor Group Limited. Pnc Group Inc reported 0% of its capital in Alkermes plc (NASDAQ:ALKS). Daiwa Sb Ltd owns 0.18% invested in Alkermes plc (NASDAQ:ALKS) for 21,113 shs. Wellington Management Grp Llp stated it has 0.19% of its capital in Alkermes plc (NASDAQ:ALKS). 4,997 were accumulated by Lpl Ltd Liability Co. Wells Fargo And Mn accumulated 342,481 shs. State Street invested in 4.57M shs. Jane Street Gru Ltd holds 0% or 48,842 shs in its capital. Dimensional Fund Advsr Ltd Partnership invested in 0% or 228,224 shs. Grp Inc One Trading L P holds 7,049 shs or 0% of its capital.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

In total 7 analysts cover Alkermes (NASDAQ:ALKS). “Buy” rating has 1, “Sell” are 2, while 4 are “Hold”. (NASDAQ:ALKS) has 14% bullish analysts. 9 are the (NASDAQ:ALKS)’s ratings reports on Jan 9, 2019 according to StockzIntelligence Inc. On Tuesday, November 6 Cantor Fitzgerald maintained Alkermes plc (NASDAQ:ALKS) rating. Cantor Fitzgerald has “Neutral” rating and $41 target. The company rating was maintained by Bank of America on Friday, July 27. On Friday, July 27 the stock has “Outperform” rating by Credit Suisse. On Thursday, December 13 the firm has “Underperform” rating by Credit Suisse given. On Wednesday, December 19 Goldman Sachs downgraded the shares of ALKS in report to “Sell” rating. Listed here are Alkermes plc (NASDAQ:ALKS) PTs and latest ratings.

19/12/2018 Broker: Goldman Sachs Old Rating: Neutral New Rating: Sell Old Target: $49 New Target: $26 Downgrade
13/12/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Underperform Old Target: $47 New Target: $31 Downgrade
29/11/2018 Broker: Stifel Nicolaus Rating: Hold
13/11/2018 Broker: Leerink Swann Rating: Market Perform New Target: $36 Initiates Coverage On
06/11/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $46 New Target: $41 Maintain
05/11/2018 Broker: PiperJaffray Rating: Neutral New Target: $40 Initiates Coverage On
07/08/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $45 Initiates Coverage On
27/07/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $57 New Target: $51 Maintain
27/07/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $56 New Target: $54 Maintain

ALKS hit $32.17 during the last trading session after $0.94 change.Currently Alkermes plc is downtrending after 35.03% change in last January 9, 2018. ALKS has 330,242 shares volume. ALKS underperformed the S&P 500 by 35.03%.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide.The firm is worth $5.00 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes.Currently it has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

For more Alkermes plc (NASDAQ:ALKS) news posted briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Businesswire.com or Benzinga.com. The titles are as follows: “Biotechs getting slammed again, XBI down almost 4% – Seeking Alpha” posted on November 12, 2018, “Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD – Seeking Alpha” on October 30, 2018, “CBM or ALKS: Which Is the Better Value Stock Right Now? – Nasdaq” with a publish date: January 09, 2019, “ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 Investing In Alkermes plc To Contact The Firm – Business Wire” and the last “Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates – Benzinga” with publication date: December 31, 2018.

Alkermes plc (NASDAQ:ALKS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.